State of New Jersey Common Pension Fund D Has $2.28 Million Holdings in Hims & Hers Health, Inc. (NYSE:HIMS)

State of New Jersey Common Pension Fund D grew its stake in Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) by 30.1% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 123,587 shares of the company's stock after purchasing an additional 28,600 shares during the period. State of New Jersey Common Pension Fund D owned approximately 0.06% of Hims & Hers Health worth $2,276,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also modified their holdings of the company. Vanguard Group Inc. raised its stake in shares of Hims & Hers Health by 1.0% in the first quarter. Vanguard Group Inc. now owns 14,310,192 shares of the company's stock valued at $221,379,000 after acquiring an additional 136,907 shares during the last quarter. Renaissance Technologies LLC boosted its stake in Hims & Hers Health by 113.1% in the second quarter. Renaissance Technologies LLC now owns 6,039,408 shares of the company's stock worth $121,936,000 after purchasing an additional 3,205,108 shares in the last quarter. Farallon Capital Management LLC grew its holdings in shares of Hims & Hers Health by 3,890.5% during the first quarter. Farallon Capital Management LLC now owns 1,676,000 shares of the company's stock worth $25,928,000 after purchasing an additional 1,634,000 shares during the last quarter. Bank of New York Mellon Corp increased its stake in shares of Hims & Hers Health by 67.5% in the second quarter. Bank of New York Mellon Corp now owns 678,602 shares of the company's stock valued at $13,701,000 after buying an additional 273,473 shares in the last quarter. Finally, M&G Plc bought a new position in shares of Hims & Hers Health in the first quarter valued at about $8,232,000. 63.52% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of brokerages have commented on HIMS. Deutsche Bank Aktiengesellschaft increased their price objective on shares of Hims & Hers Health from $23.00 to $27.00 and gave the stock a "hold" rating in a report on Wednesday, November 6th. Canaccord Genuity Group increased their price target on shares of Hims & Hers Health from $24.00 to $28.00 and gave the company a "buy" rating in a research note on Tuesday, November 5th. TD Cowen boosted their price objective on shares of Hims & Hers Health from $25.00 to $28.00 and gave the stock a "buy" rating in a research report on Friday, November 8th. Bank of America lowered Hims & Hers Health from a "buy" rating to an "underperform" rating in a research report on Thursday. Finally, Needham & Company LLC began coverage on Hims & Hers Health in a research report on Thursday, August 22nd. They set a "buy" rating and a $24.00 target price for the company. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating and seven have issued a buy rating to the stock. According to MarketBeat.com, Hims & Hers Health currently has an average rating of "Hold" and an average price target of $21.21.

Hims & Hers Health Price Performance

Shares of NYSE HIMS traded down $1.21 during midday trading on Friday, reaching $19.64. 21,856,867 shares of the stock were exchanged, compared to its average volume of 9,210,903. Hims & Hers Health, Inc. has a 12 month low of $7.40 and a 12 month high of $30.44. The business has a 50-day simple moving average of $19.64 and a two-hundred day simple moving average of $18.78. The company has a market capitalization of $4.22 billion, a price-to-earnings ratio of 44.55 and a beta of 1.06.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last posted its earnings results on Monday, November 4th. The company reported $0.32 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.06 by $0.26. The firm had revenue of $401.56 million during the quarter, compared to analysts' expectations of $382.20 million. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. The company's revenue was up 77.1% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.04) earnings per share. Equities research analysts expect that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, insider Soleil Boughton sold 2,339 shares of the firm's stock in a transaction that occurred on Tuesday, September 17th. The shares were sold at an average price of $16.50, for a total transaction of $38,593.50. Following the completion of the transaction, the insider now directly owns 176,952 shares of the company's stock, valued at $2,919,708. This trade represents a 1.30 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Oluyemi Okupe sold 142,886 shares of the business's stock in a transaction on Wednesday, November 13th. The stock was sold at an average price of $29.93, for a total transaction of $4,276,577.98. Following the completion of the sale, the chief financial officer now directly owns 112,186 shares in the company, valued at approximately $3,357,726.98. This represents a 56.02 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 996,961 shares of company stock worth $20,256,416 over the last ninety days. Company insiders own 17.71% of the company's stock.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.